Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 18/20 | 1.00 |
| ▸ | PKN1 | Q16512 | 4/20 | 0.65 |
| ▸ | PKN2 | Q16513 | 4/20 | 0.65 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5467157 | 0.87 | CDC7 (0.77) | CDC7PKN1PKN2CCNA2CDK2 | |
| SCHEMBL5451409 | 0.84 | CDC7 (1.00) | CDC7PKN1PKN2CCNA2CDK2 | |
| SCHEMBL5469534 | 0.84 | CDC7 (1.00) | CDC7PKN1PKN2CCNA2CDK2 | |
| SCHEMBL3430765 | 0.84 | CDC7 (1.00) | CDC7PKN1PKN2CCNA2CDK2 | |
| SCHEMBL5465946 | 0.84 | CDC7 (1.00) | CDC7PKN1PKN2CCNA2CDK2 | |
| SCHEMBL5454510 | 0.82 | CDC7 (1.00) | CDC7PKN1PKN2CCNA2CDK2 | |
| SCHEMBL5467066 | 0.82 | CDC7 (1.00) | CDC7PKN1PKN2CCNA2CDK2 | |
| SCHEMBL5451364 | 0.82 | CDC7 (1.00) | CDC7PKN1PKN2CCNA2CDK2 | |
| SCHEMBL5452175 | 0.82 | CDC7 (1.00) | CDC7PKN1PKN2CCNA2CDK2 | |
| SCHEMBL5462592 | 0.81 | CDC7 (0.69) | CDC7PKN1PKN2CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007068728-A2 | N-SUBSTITUTED PYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2007-06-21 | — | — | WO | claimed |
| US-20070142414-A1 | N-substituted pyrrolopyridinones active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2007-06-21 | — | — | US | claimed |
| US-20070142414-A1 | N-substituted pyrrolopyridinones active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142414-A1 | N-substituted pyrrolopyridinones active as kinase inhibitors | CDK2, MAP3K19, MAP3K7 | CDC7 251/4885PKN1 94/4885PKN2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.